MARKET

INBX

INBX

Inhibrx Biosciences Inc
NASDAQ
89.47
+2.06
+2.36%
After Hours: 90.06 +0.59 +0.66% 19:32 12/05 EST
OPEN
88.32
PREV CLOSE
87.41
HIGH
90.58
LOW
85.61
VOLUME
140.32K
TURNOVER
--
52 WEEK HIGH
90.58
52 WEEK LOW
10.81
MARKET CAP
1.30B
P/E (TTM)
-8.9259
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INBX last week (1124-1128)?
Weekly Report · 6d ago
Inhibrx Biosciences Reports Promising Q3 2025 Results
TipRanks · 11/25 03:57
Weekly Report: what happened at INBX last week (1117-1121)?
Weekly Report · 11/24 10:23
Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap
Seeking Alpha · 11/21 16:03
Weekly Report: what happened at INBX last week (1110-1114)?
Weekly Report · 11/17 10:23
Assessing Inhibrx Biosciences (INBX) Valuation After Positive Phase 2 Ozekibart Trial Results
Simply Wall St · 11/15 10:23
Inhibrx options imply 7.3% move in share price post-earnings
TipRanks · 11/14 19:05
Inhibrx Biosciences GAAP EPS of -$2.28
Seeking Alpha · 11/14 11:34
More
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Webull offers Inhibrx Biosciences Inc stock information, including NASDAQ: INBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INBX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INBX stock methods without spending real money on the virtual paper trading platform.